Rocket Pharmaceuticals' proposed public offering of its common stock could lead to equity dilution for existing shareholders. This often results in a decrease in the stock's price in the short term as the market adjusts to the increased number of shares. However, the long-term impact will depend on how the company uses the raised capital.